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ABSTRACT
 Objective: Hürthle cell tumors constitute about 5% 
of thyroid neoplasms. They have malignant potential, 
behaving very aggressively compared to other differenti-
ated thyroid cancers. The objective of this case report is to 
describe a case of a Hürthle cell carcinoma with a single 
large metastasis in the liver presenting almost 17 years 
after hemithyroidectomy. We highlight the difficulties in 
making a histologic diagnosis and the unpredictable nature 
of this cancer.
 Methods: The patient history and biochemistry were 
detailed. Thyroid function tests analyzed on multiple 
platforms (single-photon emission computed tomogra-
phy, dynamic magnetic resonance imaging, technetium-
99m bone scan, and radioactive iodine) were used to aid 
biochemical and radiologic diagnosis.
 Results: The patient’s thyroid function test showed 
persistently low free thyroxine concentrations with normal 
thyroid stimulating hormone and free triiodothyronine, 
suggesting rapid deiodination in the context of a large liver 
lesion. Radiologic and morphologic appearances of the 
liver lesion led to an initial misdiagnosis of primary hepato-
cellular carcinoma, revised to metastatic Hürthle cell carci-
noma after positive immunochemistry. Nonparathyroid 
hormone-related intractable hypercalcemia of malignancy 
with an unusual pattern of elevated 1,25-dihydroxyvitamin 
D and raised fibroblast growth factor 23 concentrations 
culminated in his demise.
 Conclusions: In Hürthle cell carcinomas treated with 
partial thyroidectomy, subsequent abnormal thyroid func-
tions tests may herald a more sinister underlying diag-
nosis. The management of Hürthle cell carcinoma relies 
heavily on the initial histology results. Histologic diag-
nosis should be sought earlier in abnormal and suspicious 
distant masses. Malignant hypercalcemia poses a great 
challenge in delayed presentations and can prove resistant 
to conventional treatments. (AACE Clinical Case Rep. 
2019;5:e204-e209)
Abbreviations:
CT = computed tomography; FGF23 = fibroblast 
growth factor 23; FT3 = free triiodothyronine; FT4 = 
free thyroxine; IGF-1 = insulin-like growth factor 1; 
MRI = magnetic resonance imaging; PTH = parathy-
roid hormone; PTHrP = parathyroid hormone–related 
peptide; TSH = thyroid stimulating hormone
CASE REPORT
 A 69-year-old man was referred to the endocrine 
department with progressive lowering of his free thyrox-
ine (FT4) concentration over the preceding 9 years. He had 
undergone a partial thyroidectomy 17 years prior for a neck 
lump, that at the time, had a histologic classification as a 
fully encapsulated Hürthle cell thyroid tumor. His medi-
cal history consisted of Barrett esophagus, hypertension, 
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osteoarthritis, a dilated aortic root, bladder and bowel irri-
tability, and a superficial facial basal cell carcinoma. Six 
years prior to presentation to the endocrine department, as 
part of his investigations for a dilated aortic root, he had 
a computed tomography (CT) aortagram, which showed a 
9.4 cm by 7.3 cm liver mass. A magnetic resonance imag-
ing (MRI) scan of the liver concluded that the mass was a 
“benign focal nodular hyperplasia” based on its morpho-
logic appearance. 
 At his presentation to the endocrine clinic he was 
taking lansoprazole, solifenacin, perindopril, bisoprolol, 
and mebeverine. Physical examination revealed marfanoid 
features with arachnodactyly, a positive Walker’s sign, and 
a high arched palate, with no specific features of acromeg-
aly. The rest of the physical examination was normal, with 
no goiter or features of hormonal deficiency or excess. 
 His biochemistry is shown in Tables 1, 2 and 3. His 
thyroid profile showed a persistently low FT4 at 6 pmol/L 
(normal, 8 to 21 pmol/L), with normal thyroid stimulating 
hormone (TSH) at 1.71 mU/L (normal, 0.35 to 3.5 mU/L), 
and normal free triiodothyronine  (FT3) at 5.9 pmol/L 
(normal, 3.8 to 6 pmol/L). The low FT4 was confirmed 
using multiple assays from different regional laborato-
ries, including Abbot, the ADVIA Centaur CP immu-
noassay system, and dissociation-enhanced lanthanide 
fluorescence immunoassay. Total thyroxine was also low 
at 10.5 nmol/L on mass spectrometry, pointing towards a 
diagnosis of secondary hypothyroidism. Although the 
patient was clinically eupituitary he had an elevated adre-
nocorticotrophic hormone at 72 ng/L (normal, <47 ng/L), 
and insulin-like growth factor 1 (IGF-1) of 29.0 nmol/L 
(normal, 5.8 to 25.0 nmol/L), raising the possibility of 
pituitary disease. Further dynamic tests carried out were 
a 75 g oral glucose load which failed to suppress growth 
hormone (GH) concentrations below 0.92 µg/L (normal, 
<0.4 µg/L), and a short tetracosactide test that was normal, 
with a peak cortisol of 676 nmol/L at 60 minutes (normal, 
>450 nmol/L). An MRI scan of his pituitary gland showed 
no abnormality. There was no evidence of skeletal metas-
tasis on technetium-99m bone scan. A repeat CT scan of 
his liver showed that the lesion had increased in size to 20 
cm in maximal diameter. Dynamic MRI scan of the liver 
with contrast showed central calcification with washout in 
the equilibrium phase followed by reduced contrast uptake 
in the hepatocyte phase, highly suggestive of primary 
hepatocellular carcinoma.
 A liver biopsy was undertaken and reported as hepato-
cellular carcinoma on its morphologic basis despite nega-
tive immunochemistry for hepatocytes, synaptophysin, 
alpha fetoprotein, and chromogranin A. However, inform-
ing the histopathologist about the history of a Hürthle cell 
tumor prompted a re-examination of the tissue block with 
immunochemistry for thyroglobulin and thyroid transcrip-
tion factor 1, which showed strong expression of these 
markers. As shown in Table 3, the serum thyroglobulin was 
also elevated to >38000 ng/ml (normal, <55 ng/ml). The 
diagnosis was subsequently revised to a metastatic Hürthle 
cell carcinoma. The initially resected thyroid gland from 
17 years prior was re-examined and reported as show-
ing a 42 mm right thyroid adenoma with some evidence 
of capsular invasion consistent with a minimally invasive 
thyroid cancer.
 After discussions amongst the multidisciplinary 
team of endocrinologists, hepatologists, oncologists, 
and surgeons, the liver mass was deemed too large for 
primary resection or embolization. Therefore, completion 
thyroidectomy was carried out and postoperative radioac-
tive iodine-131 was administered. However, there was no 
uptake of radioactive iodine on the single-photon emission 
CT suggesting that the mass had dedifferentiated. Whole 
body planar imaging showed no evidence of other metasta-
ses. Histology of the remnant thyroid showed there was no 
evidence of neoplasia. 
 Over the next 2 weeks, the patient developed intrac-
table hypercalcemia with adjusted calcium measuring up to 
4.2 mmol/L (normal, 2.1 to 2.6 mmol/L), with a suppressed 
parathyroid hormone (PTH) at 1.1 pmol/L (normal, 1.6 to 
6.9 pmol/L) and undetectable parathyroid hormone–relat-
ed peptide (PTHrP) at <1 pmol/L (normal, <1.8 pmol/L). 
His 1,25-dihydroxyvitamin D was elevated at 258 pmol/L 
(normal, 55 to 138 pmol/L) and fibroblast growth factor 
23 (FGF23) was significantly elevated at 8890 RU/mL 
(normal, <100 RU/mL). This severe hypercalcemia failed 
to respond to conventional treatment with intravenous 
Table 1
Thyroid Function Tests
Date 09/06/2006 08/07/2009 31/05/2011 24/12/2012 11/02/2013 28/11/2016 12/12/2016 03/01/2017 11/05/2017
Thyroid stimulating 
hormone (normal, 
0.35-3.5 mIU/L)
1.58 1.23 0.93 1.71 1.4 2.13 1.82a 1.22 0.59
Free thyroxine 
(normal, 8-21 pmol/L)
10 11 7 6 6 <5 <5a <5 6
Free tri-iodothyronine
(normal, 3.8-6.0 pmol/L)
5.9 6.7
aTests that prompted urgent referral to the endocrinologists.
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fluids, oral glucocorticoids, bisphosphonates, cinacalcet, 
calcitonin, or denosumab. Renal failure ensued as a conse-
quence of his persistent hypercalcemia and the patient 
became increasingly confused and frail. An octreotide scan 
was planned but the patient was not fit enough to undergo 
the test, and was palliated and died of progressive disease. 
The family declined a postmortem examination.
 
DISCUSSION
 We present a case of a fatal metastatic Hürthle cell 
carcinoma with highly unusual biochemistry of persis-
tently low FT4, elevated IGF-1, and severe hypercalcemia, 
presenting 17 years after initial diagnosis. 
 Hürthle cells, also known as oncocytes or oxyphilic 
cells, can be found in benign and malignant thyroid carci-
nomas. They are large polygonal cells with an eosinophil-
ic-rich granular cytoplasm and abundant mitochondria 
derived from thyroid follicular epithelium. The oncocytic 
transformation of follicular cells can be caused by chron-
ic inflammation (thyroiditis), hyperthyroidism (Graves 
disease) or a hyperplastic multinodular goiter (1). Hürthle 
cells exhibit alterations in mitochondrial deoxyribonucle-
ic acid (DNA) genes and nuclear DNA genes coding for 
proteins involved in oxidative phosphorylation. However, 
the exact mechanism of tumorigenesis still remains unclear 
(2). Histologic evidence of capsular or vascular invasion 
and distant metastasis reliably distinguishes benign from 
malignant disease (3,4). Factors predisposing to reduced 
survival rates in Hürthle cell carcinomas are advanced age, 
male gender, and nodule size (5). 
 The World Health Organization classifies Hürthle cell 
carcinomas as an oxyphilic variant of follicular carcinomas 
(3), but some authors consider them as a separate clini-
cal entity based on genomic studies (6). Female to male 
preponderance is 2:1, with a mean age of diagnosis being 
50 years (3). Distant metastases are seen in up to a third 
of cases (5), with bone and lungs being the most frequent 
sites (7). As with other thyroid carcinomas, the neoplastic 
prediction is dependent on the accuracy of the initial histo-
logic diagnosis in terms of capsular/lymphovascular inva-
sion. Because of these difficulties, one critical pathologic 
appraisal resulted in diagnostic revision of 28% of their 
cases with Hürthle cell carcinomas (8). As with our case, 
patients who have undergone a partial hemithyroidectomy 
or lobectomy may present with distant metastatic disease 
without involving the residual thyroid tissue or local lymph 
nodes (9). Progression towards metastatic disease can be 
very slow and it may take years before it manifests, hence 
a high degree of clinical suspicion and long term follow up 
is warranted.
 Metastatic Hürthle cell carcinomas can present with 
a wide range of biochemical abnormalities. In our case 
the patient presented with a persistently low FT4, elevat-
ed IGF-1 and thyroglobulin, and severe hypercalcemia. 
Animal studies have shown that thyroglobulin and IGF-1 
play important roles in biosynthesis of thyroid hormones 
(10,11). Both in vitro and in vivo rat studies suggested 
that thyroglobulin downregulates the synthesis of thyroid 
hormones and also reduces the uptake of iodide by the 
follicular cells irrespective of TSH concentration (12,13). 
This could partly explain why our patient has a low FT4 
concentration and a lack of radioactive iodine uptake. 
In addition, normal thyroid tissue possesses type 1 and 
type 2 iodothyronine deiodinase enzymes which results 
in catalyzation of FT4 to FT3 by outer ring deiodination 
(14). A few studies have shown overexpression of type 1 
and type 2 deiodinases in large and metastatic follicular 
cell carcinomas causing rapid conversion of FT4 to FT3 
with a subsequently raised FT3/FT4 ratio, whilst main-
taining a TSH concentration within the reference range 
(15,16). These authors showed that resection of the tumor 
resulted in normalization of the FT3/FT4 ratio. Our case 
also showed similar biochemistry (see Table 1) and there 
was some recovery of FT4 after completion thyroidectomy 
and thyroxine replacement with accompanied mild triio-
dothyronine (T3) toxicosis (FT3 = 6.7 pmol/L). However, 
this pattern of biochemistry is very unusual and only there 
are only a few related case reports in the literature with 
metastatic follicular thyroid carcinoma (15,16). To our 
knowledge, this is the first case where this phenomenon 
has been reported in a metastatic Hürthle cell carcinoma. 
Table 2
Subsequent Hormonal Profile
Adrenocorticotrophic hormone (normal, <42 ng/L) 72
Follicle stimulating hormone (normal, <8 IU/L) 6.3
Luteinizing hormone (normal, 3-8 IU/L) 7.2
Prolactin (normal, 53-360 mIU/L) 135
Random growth hormone (µg/L) 3.13
Testosterone (normal, 9.9-27.8 nmol/L) 22.5
Total thyroxine (normal, 69-141 nmol/L) 12.3
Thyroid stimulating hormone (normal, 0.4-4.0 mU/L) 1.41
Free thyroxine (normal, 9-20 pmol/L) 2.7a
Calculated free thyroxine (pmol/L) 1.5a
Free tri-iodothyronine (normal, 3.5-6.5 pmol/L) 5.93a
Thyroid binding globulin (normal, 14-31 µg/mL) 16.6a
Total thyroxine (normal, 69-141 nmol/L) 12.4a
Total thyroxine (mass spec) 10.5a
Short (250 µg) tetracosactide test (cortisol nmol/L)
Time 0 331
Time 30 minutes (>450 nmol/L) 552
Time 60 minutes 676
aThese results were from samples sent to different regional 
laboratories using multiple assays including Abbot, the ADVIA 
Centaur CP immunoassay system, dissociation-enhanced lanthanide 
fluorescence immunoassay, and mass spectrometry.
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Table 3
Further Biochemical Results
Growth hormone suppression test GH (µg/L) Glucose (mmol/L)
–30 minutes 2.8 5.8
–10 minutes 2.51 5.6
0 minutes 2.77 5.6
30 minutes 1.95 6.8
60 minutes 2.52 8.5
90 minutes 2.46 8.7
120 minutes 1.82 9.1
150 minutes 0.92 7.0
Other tests
Insulin-like growth factor 1 (normal, 5.8-25.5 nmol/L) 29
Adjusted calcium (normal, 2.10-2.60 mmol/L) 3.28
Parathyroid hormone (normal, 1.6-6.9 pmol/L) 1.1
Parathyroid hormone-related peptide (normal, <1.8 pmol/L) <1
Phosphate (normal, 0.8-1.45 mmol/L) 1.59
25-hydroxyvitamin D (nmol/L) 50
1,25-dihydroxyvitamin D (normal, 55-139 pmol/L) 258
24,25-dihydroxyvitamin D (nmol/L) 2.6
1,25-dihydroxyvitamin D:24,25-dihydroxyvitamin D ratio 99
Vasoactive intestinal peptide (normal, <30 pmol/L) 6
Pancreatic polypeptide (normal, <300 pmol/L) 68
Somatostatin (normal, <150 pmol/L) 48
Gastrin (normal, <40 pmol/l) 123
Chromogranin A (normal, <60 pmol/L) 58
Glucagon (normal, <50 pmol/L) 43
Chromogranin B (normal, <150 pmol/L) 110
Fibroblast Growth Factor-23 (normal, <100 RU/mL) 8890
Serum iodine (normal, 0.32-0.63 µmol/L) 0.22
Thyroglobulin (ng/ml) (antithyroglobulin negative) 38200
Calcitonin (normal, <11.8 ng/L) <1.0
Abbreviation: GH = growth hormone.
This finding is in contrast to consumptive hypothyroidism 
caused by type 3 iodothyronine deiodinase activity trig-
gering degradation of FT4 and FT3 into inactive metabo-
lites, reverse T3 and 3,3'-diiodiothyronine, respectively, by 
inner ring deiodination. Overexpression of type 3 iodothy-
ronine deiodinase has been reported with hepatic heman-
giomas and nonvascular tumors as a rare form of acquired 
consumptive hypothyroidism, in which both FT4 and 
FT3 are low with elevated TSH and require supraphysi-
ologic doses of thyroxine to achieve a euthyroid state (17). 
However, we were unable to assess iodothyronine deiodin-
ase activity in the resected thyroid tissue or the liver biopsy 
which we acknowledge is a limitation.
 Approximately 80% of malignancy related hypercal-
cemia is mediated by PTHrP, with approximately 20% 
driven by osteolytic bony metastasis, and a small percent-
age attributed to ectopic 1,25-hydroxylase activity and 
ectopic PTH (18,19). In our case, the absence of PTHrP, 
PTH, and skeletal disease suggested the hypercalcemia 
was likely due to ectopic 1-alpha-hydroxylase activity 
resulting in the elevated 1,25-dihydroxyvitamin D concen-
trations and malignant hypercalcaemia. This phenomenon 
is well described in cases of sarcoidosis, lymphomas, and 
ovarian germ cell tumors (20-22), but has not been previ-
ously reported in the literature with metastatic Hürthle 
cell thyroid carcinoma. It is also interesting to note that 
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the patient’s FGF23 was elevated but did not suppress the 
1,25-dihydroxyvitamin D concentrations, as previous work 
has reported negative feedback of FGF23 on renal 1-alpha-
hydroxylase activity (23). This severe hypercalcemia 
proved resistant to conventional treatment with intrave-
nous fluids, glucocorticoids, bisphosphonates, calcitonin, 
cinacalcet, and denosumab. Previous work has shown that 
targeting the 1-alpha-hydroxylase activity with the azole 
group of antifungals can achieve normocalcemia in granu-
lomatous diseases (22). The use of somatostatin analogues 
for malignant humoral hypercalcemia has also been report-
ed with good results (24). However, in the present case, 
the patient deteriorated swiftly and we were unable to try 
these treatments. 
 The curative management of Hürthle cell carcinomas 
is chiefly surgical. Radioactive iodine has shown improved 
survival rates in iodine avid tumors (25); however, only 
up to 53% of metastatic tumors are iodine avid (26). 
Indium-111 octreotide scintigraphy has some role in the 
diagnosing and monitoring of metastatic disease in nonio-
dine avid metastatic disease (27). There is a limited role 
for palliative radiotherapy, such as the use of radioligand 
therapy, with somatostatin analogues, or kinase inhibitors, 
which have been used with variable results (27-31).
 Hürthle cell carcinomas are more aggressive in nature 
than other differentiated thyroid neoplasms, with a greater 
propensity to metastasize to distant sites (6). Bhattacharya 
et al (5) reported a nonsignificant reduction in survival 
rates between nonmetastatic Hürthle cell carcinomas and 
follicular thyroid cancer with an overall survival time 
of 109 months. Due to the relative rarity of Hürthle cell 
carcinomas and its unpredictable behavior, there are varied 
opinions on how best to manage them, with more consis-
tency being advocated with a longer term follow-up (32). 
 
CONCLUSION
 In summary, our case illustrates that Hürthle cell carci-
noma can manifest with various biochemical abnormali-
ties, including isolated low FT4, severe hypercalcemia, 
and ectopic growth hormone excess, and can present in 
distant organs aggressively after a prolonged period of 
dormancy. Clinicians should consider this as a potential 
diagnosis when presented with unusual biochemistry if a 
Hürthle cell carcinoma has been previously diagnosed, no 
matter how long ago.
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